To develop a novel therapeutic strategy for overcoming the drug resistance conferred by the PIK3CD-S overexpression in AA PCa, we further explore the possibility of using a splicing inhibitor as a single agent or in combination with a PI3K/PI3Kδ inhibitor as synergistic drug therapy. This evidence concerns the gene PIK3CD and posterior cortical atrophy.